Literature DB >> 2182673

Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.

J J Treanor1, F K Roth, R F Betts.   

Abstract

To investigate the immunogenicity and protective efficacy of cold-adapted influenza vaccine in individuals with underlying immunity to influenza A virus, we administered cold-adapted H1N1 and H3N2 vaccines to adults with prevaccination serum hemagglutination inhibition antibody titers of 1:16 or more and challenged them 1 month afterwards with homologous wild-type influenza A virus. Both cold-adapted vaccines were immunogenic in seropositive adults. In addition, individuals receiving cold-adapted vaccines had lower rates of virus shedding and illness following challenge with wild-type influenza virus than did unvaccinated seropositive volunteers.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2182673      PMCID： PMC269668          DOI： 10.1128/jcm.28.3.596-599.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

2.  Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults.

Authors:  S D Sears; M L Clements; R F Betts; H F Maassab; B R Murphy; M H Snyder
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

3.  Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers.

Authors:  B R Murphy; M L Clements; H P Madore; J Steinberg; S O'Donnell; R Betts; D Demico; R C Reichman; R Dolin; H F Maassab
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

4.  Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine.

Authors:  M L Clements; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

5.  Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine.

Authors:  P R Johnson; S Feldman; J M Thompson; J D Mahoney; P F Wright
Journal:  J Med Virol       Date:  1985-12       Impact factor: 2.327

6.  Cold-adapted recombinant influenza A virus vaccines in seronegative young children.

Authors:  P F Wright; N Okabe; K T McKee; H F Maassab; D T Karzon
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

7.  Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases.

Authors:  G J Gorse; R B Belshe; N J Munn
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

8.  Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus.

Authors:  S Feldman; P F Wright; R G Webster; P K Roberson; J Mahoney; J Thompson; M Doolittle; L Lott; P Johnson; R C Christoph
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

9.  Serum antibody responses in naturally occurring influenza A virus infection determined by enzyme-linked immunosorbent assay, hemagglutination inhibition, and complement fixation.

Authors:  H P Madore; R C Reichman; R Dolin
Journal:  J Clin Microbiol       Date:  1983-12       Impact factor: 5.948

10.  Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine.

Authors:  P R Johnson; S Feldman; J M Thompson; J D Mahoney; P F Wright
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226
View more
  6 in total

1.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.

Authors:  Alison Han; Lindsay M Czajkowski; Amanda Donaldson; Holly Ann Baus; Susan M Reed; Rani S Athota; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

3.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

Review 4.  The human side of influenza.

Authors:  Christine M Oshansky; Paul G Thomas
Journal:  J Leukoc Biol       Date:  2012-02-23       Impact factor: 4.962

Review 5.  Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Authors:  Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Influenza Other Respir Viruses       Date:  2011-06-13       Impact factor: 4.380

6.  A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.

Authors:  Daniel J Fullen; Bryan Murray; Julie Mori; Andrew Catchpole; Daryl W Borley; Edward J Murray; Ganesh Balaratnam; Anthony Gilbert; Alex Mann; Fiona Hughes; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.